March 24, 2026 a 08:38 pm
MDT: Analysts Ratings - Medtronic plc
Medtronic plc, a leader in medical technology, has received positive analyst ratings over recent months. The company's diverse portfolio in cardiovascular, medical-surgical, and neurology segments contributes to its strong market position. The overall analyst sentiment remains optimistic, with considerable ratings towards 'Buy' and minimal concern from 'Sell' recommendations, indicating solid confidence in the stock's potential for growth.
Historical Stock Grades
Examining recent ratings for Medtronic plc, there's a notable consistency in positive sentiment surrounding the stock. Below is a detailed view of the latest analyst ratings.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 14 | |
| Hold | 12 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment for Medtronic has demonstrated a stable yet positive trajectory. Here are key observations:
- The total number of ratings has remained relatively consistent, with slight fluctuations.
- Strong Buy ratings have slightly decreased, while Buy ratings remain robust.
- Hold recommendations initially increased but have stabilized recently, indicating cautious optimism.
Percentage Trends
Examining Medtronic's rating trends reveals subtle but important shifts in analyst sentiment:
- Strong Buy ratings have marginally decreased from 20% to 15% over the months.
- Buy ratings have maintained a significant presence, consistently garnering 45-48% of total ratings.
- Hold ratings saw a notable increase from 23% to approximately 38%, reflecting a growing prudence among analysts.
- The slight increase in Hold ratings suggests more analysts are cautious but not overtly bearish on the stock.
Latest Analyst Recommendations
Recent analyst recommendations for Medtronic emphasize steadiness and confidence:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-10 | Buy | Buy | Needham |
| 2026-02-18 | Neutral | Neutral | Baird |
| 2026-02-18 | Neutral | Neutral | JP Morgan |
| 2026-02-18 | Overweight | Overweight | Barclays |
| 2026-02-17 | Buy | Buy | Needham |
Analyst Recommendations with Change of Opinion
Some notable upgrades reflect growing confidence and potential positive outlook for Medtronic:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-09 | Buy | Hold | Needham |
| 2026-01-06 | Outperform | Market Perform | William Blair |
| 2025-11-19 | Neutral | Sell | Goldman Sachs |
| 2025-06-30 | Peer Perform | Underperform | Wolfe Research |
| 2025-03-04 | Buy | Neutral | Citigroup |
Interpretation
Overall, the analyst sentiment towards Medtronic is largely positive, with stable trends in Buy and Strong Buy recommendations. There is a cautious yet optimistic approach as evidenced by a rise in Hold suggestions. Recent upgrades point towards increasing confidence in the company's performance, suggesting a strong future outlook.
Conclusion
In summary, Medtronic plc has demonstrated consistent analyst backing with a majority leaning towards 'Buy' recommendations. The steady ratings suggest a stable outlook with limited downside risk. Analysts appear to be cautiously optimistic, with recent recommendation upgrades indicating potential for upward momentum. However, an increase in Hold ratings reflects a degree of cautiousness in the market.